Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congesitive heart failure (CHF). The channel includes news on HFpEF and HFrEF.

 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019

December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart...

The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment...

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session.

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session. Photo by AHA/Phil McCarten

Blog | Heart Failure | November 21, 2019

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including...

Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety...

The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at...

 doctor heart failure patient from CorAssist
News | AHA | November 14, 2019

November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering...

One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.

One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.

News | November 06, 2019

November 6, 2019 — Cleveland Clinic announced the Top 10...

Greater Left Ventricular Mass Increases Risk of Heart Failure
News | Magnetic Resonance Imaging (MRI) | October 21, 2019

October 21, 2019 — Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger...

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor

October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's...

Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019

October 16, 2019 — Researchers have shown for the first time in preclinical studies that the...

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019

October 3, 2019 – The three-year results from the...

A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor.

A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor. (Photos by Dave Fornell)

Blog | University of Colorado Hospital | October 02, 2019

I recently had the opportunity to conduct an onsite visit to the...

Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019

September 27, 2019 — Ancora Heart Inc. announced results from an interim analysis of...

Overlay Init